Gland Pharma Limited (NSE: GLAND) and Glenmark Pharmaceuticals Limited (NSE: GLENMARK) are both listed in the Medicinal Chemicals and Botanical Products industry. Gland Pharma has a market capitalisation of ₹50,589 Cr and Glenmark Pharmaceuticals ₹67,220 Cr, as of 9 Nov 2026. Their P/E ratios are 49.2 and 49.4 respectively. Return on equity is 10.53% for Gland Pharma and 14.07% for Glenmark Pharmaceuticals. Over one year, Gland Pharma's share price is up 70.3% and Glenmark Pharmaceuticals's is up 40.7%.
| Metric | Gland Pharma | Glenmark Pharmaceuticals |
|---|---|---|
| NSE Symbol | GLAND | GLENMARK |
| BSE Code | 543245 | 532296 |
| Share Price | ₹3,285.00 | ₹2,671.10 |
| Market Cap | ₹50,589 Cr | ₹67,220 Cr |
| P/E Ratio | 49.2 | 49.4 |
| Return on Equity | 10.53% | 14.07% |
| Return on Assets | 6.27% | 14.11% |
| Dividend Yield | 0.65% | 0.21% |
| Beta (1Y) | 0.49 | 0.4 |
| 1-Year Price Change | +70.3% | +40.7% |
| 3-Month Price Change | +23.2% | +18.6% |
| 52-Week Range | ₹1,573.60 – ₹3,374.00 | ₹1,807.00 – ₹2,714.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹1,834 Cr | ₹4,157 Cr |
| Quarterly Net Profit | ₹291 Cr | ₹264 Cr |
| Net Margin | 15.9% | 6.3% |
| EPS (Basic, Quarter) | ₹17.62 | ₹9.35 |
| Results Basis | consolidated | consolidated |
| Headquarters | Hyderabad, Telangana | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, g…
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topica…
Glenmark Pharmaceuticals has a market capitalisation of ₹67,220 Cr, against ₹50,589 Cr for Gland Pharma as of 9 Nov 2026, about 1.3 times the size by market cap.
Gland Pharma has a P/E of 49.2 and Glenmark Pharmaceuticals a P/E of 49.4 as of 9 Nov 2026.
Gland Pharma has a return on equity of 10.53% and Glenmark Pharmaceuticals 14.07%.
Gland Pharma's share price is up 70.3% over one year and Glenmark Pharmaceuticals's is up 40.7%.
Gland Pharma reported revenue of ₹1,834 Cr and net profit of ₹291 Cr for Q2 FY27. Glenmark Pharmaceuticals reported revenue of ₹4,157 Cr and net profit of ₹264 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.